Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Cash And Cash Equivalents : $9.97 Mil (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Cash And Cash Equivalents?

Tribute Pharmaceuticals Canada's quarterly cash and cash equivalents increased from Mar. 2015 ($4.40 Mil) to Jun. 2015 ($14.23 Mil) but then stayed the same from Jun. 2015 ($14.23 Mil) to Sep. 2015 ($9.97 Mil).

Tribute Pharmaceuticals Canada's annual cash and cash equivalents increased from Dec. 2012 ($2.31 Mil) to Dec. 2013 ($2.64 Mil) and increased from Dec. 2013 ($2.64 Mil) to Dec. 2014 ($3.04 Mil).

Tribute Pharmaceuticals Canada Cash And Cash Equivalents Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada Cash And Cash Equivalents Chart

Tribute Pharmaceuticals Canada Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Cash And Cash Equivalents

Get a 7-Day Free Trial

4.32

2.18

2.31

2.64

3.04

Tribute Pharmaceuticals Canada Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Cash And Cash Equivalents	Get a 7-Day Free Trial															26.09	3.04	4.40	14.23	9.97

Tribute Pharmaceuticals Canada Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Tribute Pharmaceuticals Canada (OTCPK:TBUFF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Tribute Pharmaceuticals Canada Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.stellarpharma.com

Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.

Executives

John M Gregory	director, 10 percent owner
Sj Strategic Investments Llc	10 percent owner
Joan P Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory	other: Member	340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines